At the 2016 European Society for Medical Oncology (ESMO) Congress, multiple Pfizer-sponsored abstracts will be presented highlighting clinical progress for eight Pfizer Oncology assets. The presentations span multiple tumor types and mechanisms of action.

Avelumab:


(Abstract 844TiP) Phase 3 Study of Avelumab in Combination with Axitinib Versus Sunitinib as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (aRCC). Motzer, R. Sunday, October 9. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.

Axitinib:


(Abstract 825P) Long-Term Duration of Axitinib Treatment in Advanced Renal Cell Carcinoma. Rini, B. Sunday, October 9. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.

Crizotinib:

(Abstract 1291TiP) Phase 1b Study of Crizotinib in Combination with Pembrolizumab in Patients (pts) with Untreated ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC). Vizcarrondo, F. Saturday, October 8. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.

Palbociclib:

(Abstract LBA15) Biomarker Analyses from the Phase 3 PALOMA-2 Trial of Palbociclib (P) with Letrozole (L) Compared with Placebo (PLB) Plus L in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer (ABC). Finn, R. Saturday, October 8. Session Type: Proffered Paper. Presentation Time: 11:00 – 12:30 CEST. Location: Vienna. (Embargoed until Saturday, October 8 at 8:15 CEST)


(Abstract 283P) Satisfaction with Cancer Treatments in HR+/HER2- Metastatic Breast Cancer Patients in a Real World Setting. De Courcy, J. Monday, October 10. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.


Sunitinib:


Early Pipeline Assets

OX40 mAB (PF-8600):

PTK7 ADC (PF-7020):

(Abstract LBA35) A Phase 1 Study of PF-06647020, an Antibody-Drug Conjugate (ADC) Targeting Protein Tyrosine Kinase 7 (PTK7), in Patients with Advanced Solid Tumors Including Platinum Resistant Ovarian Cancer (OVCA). Sachdev, J. Saturday, October 8. Session Type: Poster Discussion. Presentation Time: 9:30 – 10:30 CEST. Location: Bern. (Embargoed until Saturday, October 8 at 8:15 CEST)

Biosimilars

PF-05280586:


(Abstract 946TIP) A Randomized Comparative Study of PF-05280586 (a Potential Biosimilar) vs Rituximab for Patients with CD20+, Low Tumor Burden, Follicular Lymphoma. Jacobs, I. Saturday, October 8. Session Type: Poster Display. Display Time: 13:00 – 14:00 CEST. Location: Hall E.

###